Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)

Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)

Abstract only

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 26; no. 15_suppl; p. 8507
Main Authors: Bociek, R. G., Kuruvilla, J., Pro, B., Wedgwood, A., Li, Z., Drouin, M., Patterson, T., Ward, R., Martell, R. E., Younes, A.
Format: Journal Article
Language:English
Published: 20-05-2008
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2008.26.15_suppl.8507